Monday , May 25 2020
Home / Michel Accad, Anish Koka /Andrew Althouse on Clinical Trial Design and Remdesivir

Andrew Althouse on Clinical Trial Design and Remdesivir

Summary:
Our guest is Andrew Althouse, statistician at the Center for Clinical Trials and Data coordination in Pittsburgh. He holds an undergraduate degree in Statistics and a PhD in Epidemiology from the University of Pittsburgh. His main area of interest is the design of randomized control trials. He discusses adaptive randomized control trials, and dissects the ...

Topics:
Michel Accad, Anish Koka considers the following as important:

This could be interesting, too:

Tyler Durden writes Get Ready For Disinfected Dice As Vegas Plans Reopening 

Wolf Richter writes Hertz Bankruptcy Threatens to Make Mess of Used-Vehicle Prices with Burst of Pent-Up Supply

Tyler Durden writes China Sets Yuan Fix At Weakest Since 2008

Tyler Durden writes Dreaming Of Visiting Japan? The Government Might Pay Half Your Expenses To Jumpstart Tourism

Our guest is Andrew Althouse, statistician at the Center for Clinical Trials and Data coordination in Pittsburgh. He holds an undergraduate degree in Statistics and a PhD in Epidemiology from the University of Pittsburgh. His main area of interest is the design of randomized control trials. He discusses adaptive randomized control trials, and dissects the recent news of the positive Remdesivir trial.

Leave a Reply

Your email address will not be published. Required fields are marked *